Biological drugs and the coming of biosimilars

Journal of Pharmacy Practice and Research

Volumn 38, Issue 2, 2008, Pages 137-139

  Power, David A ^a   Ford, David ^b  

^a AUSTIN HEALTH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; INTERLEUKIN 2; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; CLINICAL PRACTICE; DRUG MARKETING; GENETIC MANIPULATION; HOSPITAL PHARMACY; PATENT; PHARMACIST; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PROFIT; WORLD HEALTH ORGANIZATION;

EID: 47749100456     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2008.tb00820.x     Document Type: Article

References (16)

1. Genazzani AA, Biggio G, Caputi AP, Del Tacca M, Drago F, Fantozzi R, et al. Biosimilar drugs: concerns and opportunities. Bio Drugs 2007; 21: 351-6.
2. Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology (Carlton) 2006; 11: 341-6.
3. Crommelin DJ, Storm G, Verrijk R, de Leede L, Jiskoot W, Hennink WE. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003; 266: 3-16.
4. Goldsmith D, Kuhlmann M, Covic A. Through the looking glass: the protein science of biosimilars. Clin Exp Nephrol 2007; 11: 191-5.
5. Starring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998; 100: 79-89.
6. Schellekens H. Follow-on biologies: challenges of the 'next generation'. Nephrol Dial Transplant 2005; 20 (suppl. 4): iv31-36.
7. Haselbeck A. Epoetins: differences and their relevance to immunogenicity. Curr Med Res Opin 2003; 19: 430-2.
8. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005; 25: 954-62.
9. Deicher R, Horl WH. Differentiating factors between erythropoiesis- stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs 2004; 64: 499-509.
10. Deechongkit S, Aoki KH, Park SS, Kerwin BA. Biophysical comparability of the same protein from different manufacturers: a case study using epoetin alfa from Epogen and Eprex. J Pharm Sci 2006; 95: 1931-43.
11. Finkelstein JB. In U.S., biosimilars still await FDA decision. J Natl Cancer Inst 2006; 98: 435.
12. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1403-8.
13. Joung J, Robertson JS, Griffiths E, Knezevic I. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters. Geneva, 19-20 April 2007. Biologicals 2008.
14. Matthews AW, Whalen J. FDA clears copycat version of human growth hormone. Wall Street J 2006; June 1: D8.
15. Harvey KJ, Harris AH, Bulfone L. The National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2007: reform or fracture? Med J Aust 2007; 187: 206-7.
16. Schellekens H. When biotech proteins go off-patent. Trends Biotechnol 2004; 22: 406-10.